SECTION-1: Identification of the substance / mixture and the company / undertaking

Catalogue Number	CS-T-43229
Product Name	Tebufenpyrad
CAS No.	119168-77-3
Category	Pesticide Standards
Synonyms	N-(4-(tert-butyl)benzyl)-4-chloro-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide
Brand	Clearsynth Labs Ltd.
Identified uses	Laboratory Chemicals
Uses advised against	Not available
Company	Clearsynth Labs Ltd. Mumbai, India
Emergency Phone #	+91-22-245045900
REACH No.	Not available

SECTION 2: Hazards identification

Disclaimer: This is sample MSDS. Please email **sales@clearsynth.com** for more details.

2.1 Classification of the substance or mixture-Regulation (EC) No 1272/2008:

Acute toxicity (Category 4)

2.2 Label Elements

Signal Word: Warning

Hazard Statement(s)

Code	Statement
H301	Not available
H317	May cause an allergic skin reaction.
H332	Harmful if inhaled.
H373	Not available

H400	Not available
H410	Not available
H302	Harmful if swallowed.
H320	Not available
H336	Not available
H351	Not available
H371	Not available
H372	Not available
H361	Not available

Precautionary Statement(s)

Code	Statement
P260	Not available
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P264	Wash hands thoroughly after handling.
P270	Not available
P271	Use only outdoors or in a well-ventilated area.
P272	Not available
P273	Not available
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P301+P316	Not available
P302+P352	IF ON SKIN: Wash with plenty of water and soap.
P304+P340	IF INHALED: Remove person to fresh air and keep comfortable for breathing.
P317	Not available
P319	Get medical help if you feel unwell.
P321	Specific treatment (see … on this label).
P330	Not available
P333+P317	Not available
P362+P364	Take off contaminated clothing and wash it before reuse.
P391	Not available

P405	Store locked up.
P501	Dispose of contents/container in accordance with local/regional/national/international regulatio
P301+P317	Not available
P203	Not available
P264+P265	Not available
P305+P351+P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if presen
P308+P316	Not available
P318	Not available
P337+P317	If eye irritation persists: Get medical help.
P403+P233	Store in a well-ventilated place. Keep container tightly closed.

SECTION 3: Composition / information on ingredients

3.1 Substance

Component : Tebufenpyrad
CAS Number : 119168-77-3
Molecular Formula : C18H24ClN3O
Molecular Weight : 333.86
Parent Chemical : -
Synonyms : N-(4-(tert-butyl)benzyl)-4-chloro-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide
Concentration : Not available

SECTION 4: First aid measures

SECTION 4: First-aid measures

4.1 Description of first aid measures
General advice: Remove contaminated clothing and shoes. Seek medical attention if symptoms persist or develop. Show this SDS to medical personnel.
Inhalation: Move person to fresh air. Keep at rest in a position comfortable for breathing. If breathing is difficult, seek medical attention.
Skin contact: Wash with plenty of soap and water. Seek medical attention if irritation develops.
Eye contact: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do. Continue rinsing. Seek medical attention if irritation persists.
Ingestion: Rinse mouth. Do NOT induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person. Seek medical attention.

4.2 Most important symptoms and effects, both acute and delayed
Not available.

4.3 Indication of any immediate medical attention and special treatment needed
Treat symptomatically. No data available.

SECTION 5: Firefighting measures

SECTION 5: Fire-fighting measures

5.1 Extinguishing media
Suitable extinguishing media: Water spray, alcohol-resistant foam, dry chemical, carbon dioxide.
Unsuitable extinguishing media: Not available.

5.2 Special hazards arising from the substance or mixture
May decompose under fire conditions to produce irritating and/or toxic fumes. Hazardous combustion products: Not available.

5.3 Advice for firefighters
Wear self-contained breathing apparatus (SCBA) and full protective gear. Use water spray to cool unopened containers. Prevent fire-fighting water from entering drains or waterways.

SECTION 6: Accidental release measures

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures
Avoid breathing dust/vapors. Avoid contact with skin and eyes. Provide adequate ventilation. Wear appropriate personal protective equipment.

6.2 Environmental precautions
Avoid release to the environment. Prevent entry into drains, surface water, and soil. Notify authorities if significant contamination occurs.

6.3 Methods and material for containment and cleaning up
Contain spill. Collect spilled material using inert absorbent (e.g., sand, earth, vermiculite) and place in a suitable, labeled container for disposal. Avoid generating dust. Clean contaminated area with suitable cleaning methods. Dispose of waste in accordance with local regulations.

6.4 Reference to other sections
See Section 8 for personal protective equipment and Section 13 for disposal considerations.

SECTION-7: Handling and storage

SECTION 7: Handling and storage

7.1 Precautions for safe handling
Use only with adequate ventilation. Avoid breathing dust/vapors. Avoid contact with skin, eyes, and clothing. Do not eat, drink, or smoke when using this product. Wash hands thoroughly after handling. Keep container tightly closed when not in use.

7.2 Conditions for safe storage, including any incompatibilities
Store in a cool, dry, well-ventilated place. Keep container tightly closed and properly labeled. Protect from moisture. Keep away from incompatible materials. Incompatible materials: Not available.

7.3 Specific end use(s)
Pesticide standard / laboratory use. Not available for other specific uses.

SECTION 8: Exposure controls / personal protection

SECTION 8: Exposure controls/personal protection

8.1 Control parameters
Occupational exposure limits: Not available.
Biological limit values: Not available.

8.2 Exposure controls
Engineering controls: Use local exhaust ventilation or general ventilation to maintain exposure below applicable limits (if established). Provide eyewash station and safety shower.
Personal protective equipment (PPE):
- Eye/face protection: Safety glasses with side shields or chemical splash goggles.
- Skin protection: Protective gloves (material not available). Wear protective clothing to prevent skin contact.
- Respiratory protection: If ventilation is inadequate or dust/aerosols are generated, use an appropriate NIOSH/EN-approved respirator (type not available).
- Hygiene measures: Wash hands after handling. Remove contaminated clothing and wash before reuse.
Environmental exposure controls: Avoid release to the environment.

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Test	Result
Appearance	No data available
IR spectrum	No data available
pH	No data available
Solubility	No data available

Property	Value
a) Physical State	No data available
b) Color	No data available
c) Odor	No data available
d) pH	No data available
e) Vapour Pressure	No data available
f) Viscosity	No data available
g) Initial Boiling Point and boiling range	No data available

Property	Value
h) Melting Point / Freezing Point	No data available
i) Auto Ignition Temperature	No data available
j) Flash Point	No data available
k) Explosion Limit, Lower	No data available
l) Explosion Limit, Upper	No data available
m) Decomposition Temperature	No data available
n) Loss on Drying	No data available
o) Relative Density	No data available
p) Solubility (in DMSO)	No data available
q) Oxidizing Properties	No data available

SECTION 10: Stability and reactivity

SECTION 10: Stability and reactivity

10.1 Reactivity
No data available.

10.2 Chemical stability
Stable under recommended storage conditions.

10.3 Possibility of hazardous reactions
No data available.

10.4 Conditions to avoid
Heat, open flames, and other ignition sources. Avoid conditions that generate dust. Other conditions: Not available.

10.5 Incompatible materials
Not available.

10.6 Hazardous decomposition products
Not available.

SECTION 11: Toxicological information

11.1 Information on toxicological effects
- Acute toxicity: LC50 (rat) = 2,660 mg/m3 /GENOTOXICITY/ /In/ in vitro cytogenetics assays with human lymphocytes tebufenpyrad /at concentrations of/ a)6, 8, 20, 40, 60, 80 ug/mL for 21 hours without activation and 8.25, 11, 27.5, 55, 82.5, 110 ug/mL for 4 hours with activation /or/ b)6.25, 12.5, 25 :g/ml for 2 hours without activation and 12.5, 25 and 50 ug/mL for 3 hours with activation, the combined data from both studies indicate that without S9 activation, tebufenpyrad induced variable but nevertheless reproducible significant increases in the percentage of aberrant cells in two of three experiments using treatment times of 20-24 hours. In general, levels causing < 40% decrease in the MI /mitotic index/ were negative, whereas concentrations causing >42% decrease in

the MI induced significant effects with reproducibly flat dose response curves. Furthermore, the same type of aberrations (chromatid breaks) was induced in both studies. Based on these considerations, it is concluded that MK-239 exhibited reproducible but weak evidence of a clastogenic response but only after prolonged exposure to cytotoxic doses and only in the absence of S9 activation. /from table/
- Skin corrosion/irritation: No data available.
- Serious eye damage/eye irritation: No data available.
- Respiratory or skin sensitization: No data available.
- Germ cell mutagenicity: /GENOTOXICITY/ /In/ in vitro cytogenetics assays with human lymphocytes tebufenpyrad /at concentrations of/ a)6, 8, 20, 40, 60, 80 ug/mL for 21 hours without activation and 8.25, 11, 27.5, 55, 82.5, 110 ug/mL for 4 hours with activation /or/ b)6.25, 12.5, 25 :g/ml for 2 hours without activation and 12.5, 25 and 50 ug/mL for 3 hours with activation, the combined data from both studies indicate that without S9 activation, tebufenpyrad induced variable but nevertheless reproducible significant increases in the percentage of aberrant cells in two of three experiments using treatment times of 20-24 hours. In general, levels causing < 40% decrease in the MI /mitotic index/ were negative, whereas concentrations causing >42% decrease in the MI induced significant effects with reproducibly flat dose response curves. Furthermore, the same type of aberrations (chromatid breaks) was induced in both studies. Based on these considerations, it is concluded that MK-239 exhibited reproducible but weak evidence of a clastogenic response but only after prolonged exposure to cytotoxic doses and only in the absence of S9 activation. /from table/
- Carcinogenicity: Cancer Classification: Suggestive Evidence of Carcinogenicity, but Not Sufficient to Assess Human Carcinogenic Potential /LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ Chronic toxicity in dogs /was studied at doses of/ 0, 1, 6, 20 mg/kg/day. NOAEL in males and females = 1 mg/kg/day; LOAEL = 6 mg/kg/day based on increased incidence of vomiting and diarrhea/loose stools and thickened gastric mucosa and chronic gastritis in the pyloric region. /from table/
- Reproductive toxicity: No data available.
- STOT-single exposure: No data available.
- STOT-repeated exposure: /LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ A uniform picture emerges for 90-day dietary or gavage studies in rats, mice and dogs. The only effects consistently observed were decreased weight gain and increased liver weight at the highest doses (about 28 mg/kg/day in the rat, 160 (M) to 220 (F) mg/kg/day in mice , and 10 mg/kg/day in dogs). Some liver hypertrophy was seen in rats, and vomiting and diarrhea occurred in dogs. /LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ Chronic toxicity in dogs /was studied at doses of/ 0, 1, 6, 20 mg/kg/day. NOAEL in males and females = 1 mg/kg/day; LOAEL = 6 mg/kg/day based on increased incidence of vomiting and diarrhea/loose stools and thickened gastric mucosa and chronic gastritis in the pyloric region. /from table/
- Aspiration hazard: No data available.

Likely routes of exposure
- No data available.

Symptoms related to the physical, chemical and toxicological characteristics
- /GENOTOXICITY/ /In/ in vitro cytogenetics assays with human lymphocytes tebufenpyrad /at concentrations of/ a)6, 8, 20, 40, 60, 80 ug/mL for 21 hours without activation and 8.25, 11, 27.5, 55, 82.5, 110 ug/mL for 4 hours with activation /or/ b)6.25, 12.5, 25 :g/ml for 2 hours without activation and 12.5, 25 and 50 ug/mL for 3 hours with activation, the combined data from both studies indicate that without S9 activation, tebufenpyrad induced variable but nevertheless reproducible significant increases in the percentage of aberrant cells in two of three experiments using treatment times of 20-24 hours. In general, levels causing < 40% decrease in the MI /mitotic index/ were negative, whereas concentrations causing >42% decrease in the MI induced significant effects with reproducibly flat dose response curves. Furthermore, the same type of aberrations (chromatid breaks) was induced in both studies.

Based on these considerations, it is concluded that MK-239 exhibited reproducible but weak evidence of a clastogenic response but only after prolonged exposure to cytotoxic doses and only in the absence of S9 activation. /from table/

SECTION 12: Ecological information

SECTION 12: Ecological information

12.1 Toxicity
Not available.

12.2 Persistence and degradability
Not available.

12.3 Bioaccumulative potential
Not available.

12.4 Mobility in soil
Not available.

12.5 Results of PBT and vPvB assessment
Not available.

12.6 Endocrine disrupting properties
Not available.

12.7 Other adverse effects
Not available.

SECTION 13: Disposal considerations

SECTION 13: Disposal considerations

13.1 Waste treatment methods
Dispose of contents/container in accordance with local/regional/national/international regulations. Do not discharge to drains or the environment.
Product/unused material: Dispose of as hazardous waste unless regulations indicate otherwise.
Contaminated packaging: Empty containers may retain residues; handle as hazardous. Do not reuse container.

SECTION 14: Transport information

SECTION 14: Transport information

14.1 UN number
Not available.

14.2 UN proper shipping name
Not available.

14.3 Transport hazard class(es)
Not available.

14.4 Packing group

Not available.

14.5 Environmental hazards
Not available.

14.6 Special precautions for user
Not available.

14.7 Maritime transport in bulk according to IMO instruments
Not available.

SECTION 15: Regulatory information

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture
Not available.

15.2 Chemical safety assessment
Not available.

SECTION 16: Other information

SECTION 16: Other information

Product name: Tebufenpyrad
Catalog No.: CS-T-43229
CAS No.: 119168-77-3
Synonyms: N-(4-(tert-butyl)benzyl)-4-chloro-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide
Supplier: Clearsynth Labs Ltd., Mumbai, India
Emergency phone: +91-22-245045900

Disclaimer: The information provided in this SDS is based on data available at the time of preparation and is believed to be accurate. It is intended for guidance for safe handling, use, processing, storage, transportation, disposal, and release, and is not considered a warranty or quality specification. Not available indicates no data was provided or located for the specific item under the conditions of this SDS.

DISCLAIMER

This MSDS is system-generated. Please verify and confirm all data, statements, and values with the Support Team before use or distribution.